Biomedical Frontiers, Inc.

Minneapolis, MN 55414

SBIR Award Summary

Total Number of Awards 7
Total Value of Awards $0.0
First Award Date 08/01/86
Most Recent Award Date 07/01/95

Key Personnel

Last Name Name Awards Contact
Hedlund Bo Erik Hedlund 7

7 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/01/95 - 12/31/96

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/25/94 - 06/30/95

Biomedical Frontiers, Inc. (BMF) has shown that non-toxic, macromolecular iron chelates can be produced by the covalent attachment of deferoxamine to biocompatible polymers and the subsequent addition of iron. Based on preliminary animal studies, these chelates show considerable promise as non-toxic contrast enhancing agents for use in magnetic...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 06/17/94 - 03/31/95

The proposed research will determine the potential utility of novel high molecular weight iron chelators as anti-cancer agents or adjuncts to other iron-depriving therapeutic strategies in the treatment of cancer. This approach takes advantage of the elevated iron requirements of many types of tumors. A series of high molecular weight iron chela...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/03/91 - 07/31/92

BIOMEDICAL FRONTIERS (BMF) has establishes that the iron chelator, deferoxamine, can be covalently bound to polymers and has demonstrated, in preclinical studies, that these conjugates can be used therapeutically as antioxidants. In the present application, BMF will evaluate these compounds, following satuation with ferric iron, as parenteral ma...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/88 - 08/31/90

In chemical and biological systems, iron is both ubiquitous and highly reactive. In a variety of circumstances, there is great need for new approaches to the removal of iron or the control of its reactivity. We have produced a series of high molecular weight iron chelators based on derivatization of a number of substrates with deferoxamine B. ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/87 - 08/31/88

In chemical and biological systems, iron is both ubiquitous and highly reactive. In a variety of circumstances, there is great need for new approaches to the removal of iron or the control of its reactivity. We have produced a series of high molecular weight iron chelators based on derivatization of a number of substrates with deferoxamine B. ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/01/86 - 02/28/87

In chemical and biological systems, iron is both ubiquitous and highly reactive. In a variety of circumstances, there is great need for new approaches to the removal of iron or the control of its reactivity. We have produced a series of high molecular weight iron chelators based on derivatization of a number of substrates with deferoxamine B. ...